Alzheimer's Disease: Functional Therapeutics in Neurodegenerative Disease
An Articles Archive
Diet - Diseases - Enzymes - Exercise - Health - Herbs - Longevity - Medicine - Minerals - Natural Health - Nutrition - Stress - Vegan - Vegetarian - Vitamins
We began this archive as a means of assisting our visitors in answering many of their health and diet questions, and in encouraging them to take a pro-active part in their own health. We believe the articles and information contained herein are true, but are not presenting them as advice. We, personally, have found that a whole food vegan diet has helped our own health, and simply wish to share with others the things we have found. Each of us must make our own decisions, for it's our own body. If you have a health problem, see your own physician.
Alzheimer's Disease: Functional Therapeutics in Neurodegenerative Disease
1. Mecocci P, MacGarvey U, Kaufman AE, Koontz D, Shoffner JM, Wallace DC, et al. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann Neurol 1993;34(4):609-616.
2. Wallace DC, Ye JH, Neckelmann, SN, Singh G, Webster KA, Greenberg BD. Sequence analysis of cDNAs for the human and bovine ATP synthase beta unit: Mitochondrial DNA genes sustain seventeen times more mutations. Curr Genet 1987;12(2):81-90.
3. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci 1994;91(23):10771-10778.
4. Janetzky B, Hauck S, Youdim MBH, Riederer P, Jellinger K, Pantucek F, et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinsonís disease. Neurosci Lett 1994;169(1-2):126-128.
5. Parker WD Jr, Parks JK, Filey CM. Cytochrome oxidase deficiency in Alzheimerís disease. Neurol 1990;40:1302-1303.
6. Parker WD, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinsonís disease. Ann Neurol 1989;26:719-723.
7. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem 1992;59:1609-1623.
8. Semchuk KM, Love EJ, Lee RG. Parkinsonís disease and exposure to agricultural work and pesticide chemicals. Neurology 1992;42:1328-1335.
9. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, et al. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1979;1(3):249-254.
10. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl- 1,2,5,6-tetrahydropyridine. Life Sci 1985;36(26):2503-2508.
11. Turski L, Bressler K, Rettig KJ, Loschmann PA, Wachtel H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991;349(6308):414-418.
12. Schulz JB, Matthews RT, Muqit MMK, Browne SE, Beal MF. Inhibition of neural nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 1995;64(2):936-939.
13. Gerlach M, Koutsilieri E, Riederer P. N-methyl-(R)-salsolinol and its relevance to Parkinsonís disease. Lancet 1998;351(9106):850-1.
14. Fleming L, Mann J.B, Bean J, Briggle T, Sanchez-Ramos JR. Parkinsonís disease and brain level of organochlorine pesticides. Ann Neurol 1994;36(1):100-3.
15. Steventon G, Williams AC, Waring RH, Pall HS, Adams D. Xenobiotic metabolism in motor neuron disease. Lancet 1988;2(8612):644-7.
16. McFadden SA. Phenotypic variation in xenobiotic metabolism and adverse environmental response: focus on sulfur-dependent detoxification pathways. Toxicology 1996;111(1-3):43-65.
17. Tanner CM. Liver enzyme abnormalities in Parkinsonís disease. Geriatrics 1991;46(Suppl 1):60-63.
18. Comprehensive Digestive Stool Analysis performed by Great Smokies Diagnostic Laboratory, Asheville, North Carolina, USA, Telephone: (800) 522-4762.
19. Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, et al. Amantadine treatment is an independent predictor of improved survival in Parkinsonís disease. Neurology 1996;46(6):1551-6.
20. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci USA 1993;90(14):6591-6595.
21. Beckman JS. Peroxynitrite versus hydroxyl radical: The role of nitric oxide in superoxide dependent cerebral injury. Ann NY Acad Sci 1994;738:69-75.
22. Wharton M, Granger DL, Durack DT. Mitochondrial iron loss from leukemia cells injured by macrophages. A possible mechanism for electron transport chain defects. J Immunol 1988;141(4):1311-1317.
23. Hantraye P, Brouillet E, Ferrante R, Palfi S, Dolan R, Matthews RT, et al. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med 1996;2(9):1017-21.
24. Bagasra O, Michaels FH, Zheng YM, Bobroski LE, Spitsin SV, Fu ZF, et al. Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci, USA 1995;92(26):12041-5.
25. Goodwin JL, Uemura E, Cunnick JE. Microglial release of nitric oxide by the synergistic action of beta-amyloid and IFN-gamma. Brain Res 1995;692(1-2):207-14.
26. Resink AM, Brahmbhatt HP, Cordell B, Dawson, VL, Dawson, DM. Nitric oxide mediates a component of B-amyloid neurotoxicity in cortical neuronal cultures. Soc Neurosci Abstr 1995;21:1010.
27. Chan PH, Epstein CJ, Kinouchi H, Kamii H, Imaizumi S, Yang G, et al. SOD-1 transgenic mice as a model for studies of neuroprotection in stroke and brain trauma. Ann NY Acad Sci 1994;738:93-103.
28. Beckman JS. The double-edged role of nitric oxide in brain function and superoxide-mediated injury. J Dev Physiol 1991;15(1):53-59.
29. Larrick JW. Metabolism of arginine to nitric oxide: An area for nutritional manipulation of human disease? J of Optimal Nutrition 1994;3(1):22-31.
30. Cross AH, Misko TP, Lin RF, Hickey WF, Trotter JL, Tilton RG. Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J Clin Invest 1994;93(6):2684-90.
31. Skolnick A. Old Chinese herbal medicine used for fever yields possible new Alzheimerís disease therapy [news]. JAMA 1997;227(10):776.
32. Bresolin N, Bet L, Binda A, Moggio M, Comi G, Nador F, et al. Clinical and biochemical correlations in mitochondrial myopathies treated with Coenzyme Q-10. Neurology 1988;38(6):892-9.
33. Ikejiri Y, Mori E, Ishii K, Nishimoto K, Yasuda M, Sasaki M. Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS. Neurology 1996;47(2):583-585.
34. Jenkins BG, et al. Investigating the neurochemistry and etiology of neurodegenerative disorders using magnetic resonance spectroscopy. In: Beal MF, editor. Mitochondria and free radicals in neurodegenerative diseases. New York: A. John Wiley & Sons, 1997. p. 457.
35. Crook TH, Tinklenberg J, Yesavage J, Petrie W, Nunzi MG, Massari DC. Effects of phosphatidylserine in aged-associated memory impairment. Neurology 1991;41(5):644-649.
36. Lombardi GF. Pharmacological treatment with phosphatidyl serine of 40 ambulatory patients with senile dementia syndrome. Minerva Med 1989;80(6):599-602.
37. Delwaide, P.J, Gyselynck-Mambourg AM, Hurlet A, Ylieff M. Double-blind randomized controlled study of phosphatidylserine in senile demented patients. Acta Neurol Scand 1986;73(2):136-140
38. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha tocopherol, or both as treatment for Alzheimerís disease. N Engl J Med 1997;336(17):1216-22.
39. White HL, Scates PW, Cooper BR. Extracts of Ginkgo biloba leaves inhibit monoamine oxidase. Life Sci 1996;58(16):1315-21.
40. Le Bars PL, Katz MM, N. Berman, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997;278(16):1327-1332.
41. Personal communication, April 1998.
42. Sheu SY, Lai CH, Chiang HC. Inhibition of xanthine oxidase by purpurogallin and silymarin group. Anticancer Res 1998;18(1A):263-7.
43. Ibid. #3.
44. Steffen V, Santiago M, de la Cruz CP, Revilla E, Machado A, Cano J. Effect of intraventricular injection of 1-methyl-4-phenylpryridinium: protection by acetyl-L-carnitine. Hum Exp Toxicol 1995;14(11):865-71.
45. Tatton WG, Ju WYH, Frase AD, et al, (1996): Treating neurodegneration of altering genomic and mitochondrial protein synthesis. Abstract on Fourth Intl. Congress of Movement Disorders, Vienna 1996;11(Suppl 1):M11.
46. Thal LJ, Carta A, Clarke WR, Ferris SH, Friedland RP, Petersen RC, et al.: A one-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimerís disease. Neurology 1996;47(3):705-711.
47. Packer L, Tritschler HJ, Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 1997;22(1-2):359-378.
48. Vatassery GT, Smith WE, Quach HT, Lai JC. In vitro oxidation of vitamin E, vitamin C, thiols and cholesterol in rat brain mitochondria incubated with free radicals. Neurochem Int 1995:26(5):527-535.
49. Ibid. # 38.
50. Poeggeler B, Reiter RJ, Tan DX, Chen LD, Manchester LC. Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis. J Pineal Res 1993;14(4):151-68.
51. Kotler M, Rodriguez C, Sainz RM; Antolin I, Menendez-Pelaez A. Melatonin increases gene expression for antioxidant enzymes in rat brain cortex. J Pineal Res 1998;24(2):83-9.
52. Perry TL, Godin DV, Hansen S. Parkinsonís disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 1982;33(3):305-310.
53. Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM, et al. Reduced intravenous glutathione in the treatment of early Parkinsonís disease. Prog Neuropsychopharmacol Biol Psychiatry 1996;20(7):1159-70.
54. Wong BK, Chan HC, Corcoran GB. Selective effects of N-acetylcysteine stereoisomers on hepatic glutathione and plasma sulfate in mice. Toxicol Appl Pharmacol 1986;86(3):421-429.
55. Pahan K, Sheikh FG, Namboodiri AM, Singh I. N-acetyl-cysteine inhibits induction of NO production by endotoxin or cytokine stimulated rat peritoneal macrophages, C6 glial cells and astrocytes. Free Radic Biol Med 1998;24:39-48.
56. Birkmayer JG. Coenzyme nicotinimide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type. Ann Clin Lab Sci 1996;26(1):1-9.
Return to: Alzheimer's Disease: Functional Therapeutics in Neurodegenerative Disease
Fair Use Notice: This document may contain copyrighted material whose use has not been specifically authorized by the copyright owners. We believe that this not-for-profit, educational use on the Web constitutes a fair use of the copyrighted material (as provided for in section 107 of the US Copyright Law). If you wish to use this copyrighted material for purposes of your own that go beyond fair use, you must obtain permission from the copyright owner.
| Home Page | Health Index |
Your Comments Are
| Home Page | Animal Issues | Archive | Art and Photos | Articles | Bible | Books | Church and Religion | Discussions | Health | Humor | Letters | Links | Nature Studies | Poetry and Stories | Quotations | Recipes | Site Search | What's New? |
Thank you for visiting all-creatures.org.